Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

被引：0
|
作者：
Jang Ho Cho
Hyun Ae Jung
Se-Hoon Lee
Jin Seok Ahn
Myung-Ju Ahn
Keunchil Park
Jong-Mu Sun
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
来源：
Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷
关键词：
Pulmonary adenocarcinoma; Epidermal growth factor receptor; Programmed cell death-ligand 1; Predictive factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1341 / 1349
页数：8
相关论文
共 50 条
  • [1] Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
    Cho, Jang Ho
    Jung, Hyun Ae
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (05) : 1341 - 1349
  • [2] Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
    Lee, Jiyun
    La Choi, Yoon
    Jung, Hyun Ae
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    EUROPEAN JOURNAL OF CANCER, 2020, 132 : 150 - 158
  • [3] SIMILAR EFFICACY OF EGFR TYROSINE KINASE INHIBITORS REGARDLESS OF TREATMENT SEQUENCE FOR THE PATIENTS WITH EGFR MUTATION-POSITIVE PULMONARY ADENOCARCINOMA
    Koo, Dong Hoe
    Kim, Kyu-Pyo
    Choi, Chang-Min
    Lee, Dae-Ho
    Lee, Jae Cheol
    Lee, Jung-Shin
    Jang, Se Jin
    Kim, Sang-We
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S409 - S410
  • [4] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Su-Hee Cho
    Lee Chun Park
    Jun Ho Ji
    Silvia Park
    Deok Won Hwang
    Ji Yean Lee
    Yoon-La Choi
    Jung-Ho Han
    Jong-Mu Sun
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 315 - 320
  • [5] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Cho, Su-Hee
    Park, Lee Chun
    Ji, Jun Ho
    Park, Silvia
    Hwang, Deok Won
    Lee, Ji Yean
    Choi, Yoon-La
    Han, Jung-Ho
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 315 - 320
  • [6] Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors
    Wang, Miao
    Zhen, Hongchao
    Jiang, Xiaoyue
    Lu, Yuting
    Wei, Yuhan
    Jin, Jiangtao
    Li, Qin
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1584 - 1595
  • [7] Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma
    Fan, Y.
    Yu, Y.
    Zhai, W.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S702 - S702
  • [8] Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
    Tang, Hui
    Geng, Ruixuan
    Xu, Xiuxiu
    Wang, Yingyi
    Zhou, Jiaxin
    Zhang, Shulan
    Zhao, Lin
    Guan, Mei
    Bai, Chunmei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] EGFR GENE MUTATION IN PULMONARY ADENOCARCINOMA
    Nguyen Hai Anh
    Tran Van Cuong
    RESPIROLOGY, 2019, 24 : 57 - 57
  • [10] Tumor Microenvironment Is Associated with Efficacy of PD-1/PD-L1 Inhibitors in Patients with Primary Pulmonary Lymphoepithelioma-Like Cancer
    Yin, K.
    Xie, Z.
    Lv, Z.
    Yang, J.
    Yang, X.
    Zhou, Q.
    Zhong, W.
    Li, L.
    Feng, H.
    Guo, W.
    Lu, D.
    Chen, Y.
    Yan, W.
    Wu, Y.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S456 - S457
12345